Showing results (1-10 of 11) with videos related to
Sort By:
Pageof 2
Methods in Molecular Biology (Clifton, N.J.)|August 27, 2011
Strategies employed for the development of PARP inhibitorsStacie Canan, Karen Maegley, Nicola CurtinMethods in Molecular Biology (Clifton, N.J.)|July 12, 2017
Strategies Employed for the Development of PARP InhibitorsStacie Canan, Karen Maegley, Nicola J CurtinPlos One|January 24, 2013
Ack1: activation and regulation by allosteryKetan S Gajiwala, Karen Maegley, RoseAnn Ferre, et al.Antiviral Research|May 31, 2011
Development of hepatitis C virus chimeric replicons for identifying broad spectrum NS3 protease inhibitorsJoseph Binder, Selwyna Tetangco, Megan Weinshank, et al.Bioorganic & Medicinal Chemistry Letters|April 30, 2013
Discovery of 2-((1H-benzo[d]imidazol-1-yl)methyl)-4H-pyrido[1,2-a]pyrimidin-4-ones as novel PKM2 activatorsChuangxing Guo, Angelica Linton, Mehran Jalaie, et al.Bioorganic & Medicinal Chemistry Letters|May 27, 2011
Design strategies to target crystallographic waters applied to the Hsp90 molecular chaperonePei-Pei Kung, Piet-Jan Sinnema, Paul Richardson, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 12, 2003
Identification of potent nontoxic poly(ADP-Ribose) polymerase-1 inhibitors: chemopotentiation and pharmacological studiesChristopher R Calabrese, Michael A Batey, Huw D Thomas, et al.Journal of Medicinal Chemistry|November 8, 2017
Discovery of a Novel and Selective Indoleamine 2,3-Dioxygenase (IDO-1) Inhibitor 3-(5-Fluoro-1H-indol-3-yl)pyrrolidine-2,5-dione (EOS200271/PF-06840003) and Its Characterization as a Potential Clinical CandidateStefano Crosignani, Patrick Bingham, Pauline Bottemanne, et al.Journal of the National Cancer Institute|January 8, 2004
Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361Christopher R Calabrese, Robert Almassy, Stephanie Barton, et al.Journal of Medicinal Chemistry|March 29, 2011
Optimization of potent, selective, and orally bioavailable pyrrolodinopyrimidine-containing inhibitors of heat shock protein 90. Identification of development candidate 2-amino-4-{4-chloro-2-[2-(4-fluoro-1H-pyrazol-1-yl)ethoxy]-6-methylphenyl}-N-(2,2-difluoropropyl)-5,7-dihydro-6H-pyrrolo[3,4-d]pyrimidine-6-carboxamideLuke Zehnder, Michael Bennett, Jerry Meng, et al.Pageof 2